ESMO 2021 | KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, presents the results of KEYNOTE-522 (NCT03036488), a Phase III study of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus placebo and neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC). 1174 patients were enrolled, and a statistically significant event-free survival (EFS) was reported in patients who received pembrolizumab, with the most frequent EFS event being distant recurrence. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.